Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | CCNK | O75909 | 2/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 8/20 | 0.37 |
| ▸ | JAK1 | P23458 | 8/20 | 0.37 |
| ▸ | JAK3 | P52333 | 8/20 | 0.37 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.37 |
| ▸ | BMP4 | P12644 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18302287 | 0.83 | DYRK1A (0.49) | DYRK1ACCNKCDK12EGFRACVR1 | |
| SCHEMBL16796062 | 0.82 | DYRK1A (0.54) | DYRK1ACCNKCDK12EGFRACVR1 | |
| SCHEMBL2346355 | 0.82 | DYRK1A (0.52) | DYRK1ACCNKCDK12EGFRACVR1 | |
| SCHEMBL2230590 | 0.82 | DYRK1A (0.35) | DYRK1ACCNKCDK12ALDH1A1GAA | |
| SCHEMBL12346403 | 0.79 | DYRK1A (0.33) | DYRK1AEGFR | |
| SCHEMBL2233900 | 0.79 | DYRK1A (0.52) | DYRK1ACCNKCDK12EGFRJAK2 | |
| SCHEMBL2350432 | 0.77 | CDK2 (0.44) | DYRK1ACCNKCDK12EGFRPIK3CD | |
| SCHEMBL2348287 | 0.77 | DYRK1A (0.44) | DYRK1ACCNKCDK12ACVR1PIK3CD | |
| SCHEMBL2233643 | 0.77 | CLK4 (0.36) | DYRK1APIK3CDALDH1A1CDK2CDK9 | |
| SCHEMBL2342714 | 0.75 | DYRK1A (0.47) | DYRK1ACCNKCDK12EGFRACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| EP-2536728-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | DYRK1A 2094/4885CCNK 686/4885CDK12 588/4885 |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | DYRK1A 1212/4885CCNK 380/4885CDK12 400/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | DYRK1A 1212/4885CCNK 380/4885CDK12 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.